SciSparc Nutraceuticals Granted An Exclusive License For The Sales Of CannAmide On The Amazon Marketplace In Canada

Jeffs' Brands Ltd JFBR, a data-driven e-commerce company operating on the Amazon Marketplace, announced that SciSparc Nutraceuticals Inc., in which the company owns a 49% equity interest, has entered into an exclusive license and distribution agreement to sell and market CannAmide on the marketplace in Canada. The exclusive license was granted by SciSparc Ltd. SPRC, a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

CannAmide is an immediate unique palmitoylethanolamide (PEA) oral formulation for the reduction of chronic pain and inflammation. CannAmide is currently available in tablet form, with each dose containing a 400mg active pharmaceutical ingredient. It has been designated a product license issuance from the Natural and Non-prescription Health Products Directorate from Health Canada, for sale as a supplement within the nutraceuticals market. PEA is a cannabinoid mimetic lipid molecule found throughout the body, including the central nervous system. Similar to cannabinoids, PEA has been shown to have neuroprotective, anti-inflammatory, analgesic and anti-convulsant properties.

SciSparc Nutraceuticals’ business focusses on the sale of hemp seeds’ oil-based products on the marketplace, under the brand Wellution. SciSparc Nutraceuticals plans on expanding its reach by marketing its brand's products in additional global markets and by broadening its products' offering.

Pursuant to the license agreement, SciSparc Nutraceuticals will purchase CannAmide at a cost price plus 3% of gross revenues. The license agreement is for a term of 12 months and may be terminated by either party with 30-days’ advance notice. The license agreement also contains customary representations, warranties, covenants and indemnification provisions.

Photo: Benzinga edit with photos by Matthias Zomer on Pexels, squarefrog on Pixabay

Related News

New Drug Based On FDA-Approved Synthetic THC And CannAmide Shows Promise In Treating Agitation In Alzhemier's

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksMarketspremium
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.